Posted on Reddit by AssociationOdd9941
The Cornell/Donner Connection: Why the Alzheimer’s Trial (SALIENT-AD) is the Ultimate De-Risking Event for Leronlimab
While the retail boards are often filled with noise, a major "institutional" signal just flashed. The **SALIENT-AD** trial (NCT07553338) is officially underway at **Weill Cornell Medicine**. This isn't just a "small pilot"—it is a surgically precise exploration into the most valuable mechanism in neurology: **Crossing the Blood-Brain Barrier (BBB) to flip the M1/M2 switch.**
**1. The "Kingmaker" Pedigree: The William H. Donner Foundation** This trial isn't funded by the company; it's funded by the **Donner Foundation**. This is a 90-year-old philanthropic "Kingmaker" that only funds foundational science at elite spots.
* **The Track Record:** They backed **Dr. Wilder Penfield** (the father of modern neurosurgery) and the early science behind **Liquid Biopsy** (now a multi-billion dollar industry).
* **The Filter:** They don't take "cold calls." Their grants are **Invitation Only**. Their scientific board—made up of elite researchers—spent 12–18 months vetting Leronlimab’s data before cutting a check. They don’t risk a century-old reputation on "junk science."
**2. The "Scientific Gauntlet" at Weill Cornell** For a trial to land at an Ivy League institution like Cornell, it has to pass a "Scientific Gauntlet":
* **Internal Review Board (IRB):** Cornell’s top docs shredded the protocol to ensure it was safe and biologically sound.
* **The BBB Factor:** This trial confirms that the scientific community accepts the data: **Leronlimab crosses the Blood-Brain Barrier.** Unlike drugs that "patrol the border," Leronlimab enters the brain tissue to bind with CCR5 directly.
**3. The Mechanism: "Healing while Blocking" (M1 to M2)** Most Alzheimer’s drugs are "hammers" that clear amyloid but cause **ARIA (brain swelling/bleeding)**. The Donner/Cornell hypothesis is different:
* **M1 (The Arsonist):** In AD, the brain is in a destructive inflammatory state.
* **M2 (The Builder):** Leronlimab is being tested for its ability to flip the switch to a "healing" state.
* **The Result:** Leronlimab acts as a **safety buffer**. It settles the "cytokine storm," allowing the brain to clear buildup without the collateral damage (swelling) that has killed so many other AD drugs.
**4. The Strategic "Exit" for Investors** Big Pharma (Biogen, Eli Lilly, Merck) typically lets foundations like Donner foot the bill for Phase 2 "Proof of Concept" trials.
* Once the **PET scans** from this 20-patient trial show a reduction in neuroinflammation, the "risk" for a buyer is gone.
* CytoDyn shifts from a "distressed biotech" to a **Platform Technology Owner**. Leronlimab becomes a *mandatory companion therapeutic* for the entire $100B+ neurology market.
**Bottom Line:** You can buy a promotional tweet, but you **cannot buy** a Donner/Cornell endorsement. The science has already survived a year of interrogation by the world’s smartest medical minds. We aren't waiting to see *if* it works; we are waiting for the PET scans to *prove* it to the Goliaths of Big Pharma.
**TL;DR:** The Donner Foundation doesn't pick "scams." They've spent 90 years picking the winners that become the "Standard of Care." They invited Leronlimab to the table because the CCR5-Alzheimer's connection is the next major pillar of medicine.
\#CYDY #Leronlimab #Alzheimers #Biotech #Neuroscience #DueDiligence #WeillCornell
The Cornell/Donner Connection: Why the Alzheimer’s Trial (SALIENT-AD) is the Ultimate De-Risking Event for Leronlimab
While the retail boards are often filled with noise, a major "institutional" signal just flashed. The **SALIENT-AD** trial (NCT07553338) is officially underway at **Weill Cornell Medicine**. This isn't just a "small pilot"—it is a surgically precise exploration into the most valuable mechanism in neurology: **Crossing the Blood-Brain Barrier (BBB) to flip the M1/M2 switch.**
**1. The "Kingmaker" Pedigree: The William H. Donner Foundation** This trial isn't funded by the company; it's funded by the **Donner Foundation**. This is a 90-year-old philanthropic "Kingmaker" that only funds foundational science at elite spots.
* **The Track Record:** They backed **Dr. Wilder Penfield** (the father of modern neurosurgery) and the early science behind **Liquid Biopsy** (now a multi-billion dollar industry).
* **The Filter:** They don't take "cold calls." Their grants are **Invitation Only**. Their scientific board—made up of elite researchers—spent 12–18 months vetting Leronlimab’s data before cutting a check. They don’t risk a century-old reputation on "junk science."
**2. The "Scientific Gauntlet" at Weill Cornell** For a trial to land at an Ivy League institution like Cornell, it has to pass a "Scientific Gauntlet":
* **Internal Review Board (IRB):** Cornell’s top docs shredded the protocol to ensure it was safe and biologically sound.
* **The BBB Factor:** This trial confirms that the scientific community accepts the data: **Leronlimab crosses the Blood-Brain Barrier.** Unlike drugs that "patrol the border," Leronlimab enters the brain tissue to bind with CCR5 directly.
**3. The Mechanism: "Healing while Blocking" (M1 to M2)** Most Alzheimer’s drugs are "hammers" that clear amyloid but cause **ARIA (brain swelling/bleeding)**. The Donner/Cornell hypothesis is different:
* **M1 (The Arsonist):** In AD, the brain is in a destructive inflammatory state.
* **M2 (The Builder):** Leronlimab is being tested for its ability to flip the switch to a "healing" state.
* **The Result:** Leronlimab acts as a **safety buffer**. It settles the "cytokine storm," allowing the brain to clear buildup without the collateral damage (swelling) that has killed so many other AD drugs.
**4. The Strategic "Exit" for Investors** Big Pharma (Biogen, Eli Lilly, Merck) typically lets foundations like Donner foot the bill for Phase 2 "Proof of Concept" trials.
* Once the **PET scans** from this 20-patient trial show a reduction in neuroinflammation, the "risk" for a buyer is gone.
* CytoDyn shifts from a "distressed biotech" to a **Platform Technology Owner**. Leronlimab becomes a *mandatory companion therapeutic* for the entire $100B+ neurology market.
**Bottom Line:** You can buy a promotional tweet, but you **cannot buy** a Donner/Cornell endorsement. The science has already survived a year of interrogation by the world’s smartest medical minds. We aren't waiting to see *if* it works; we are waiting for the PET scans to *prove* it to the Goliaths of Big Pharma.
**TL;DR:** The Donner Foundation doesn't pick "scams." They've spent 90 years picking the winners that become the "Standard of Care." They invited Leronlimab to the table because the CCR5-Alzheimer's connection is the next major pillar of medicine.
\#CYDY #Leronlimab #Alzheimers #Biotech #Neuroscience #DueDiligence #WeillCornell
25
